Target Name: RBM23
NCBI ID: G55147
Review Report on RBM23 Target / Biomarker Content of Review Report on RBM23 Target / Biomarker
RBM23
Other Name(s): RBM23 variant 3 | RNA binding motif protein 23 | RBM23 variant 2 | MGC4458 | RNA binding motif protein 23, transcript variant 2 | CAPER beta | Coactivator of activating protein-1 and estrogen recep- tors beta | RNA binding motif protein 23, transcript variant 1 | RBM23 variant 1 | PP239 | Splicing factor SF2 | RNPC4 | Probable RNA-binding protein 23 (isoform 1) | splicing factor SF2 | RNA-binding motif protein 23 | RNA-binding region (RNP1, RRM) containing 4 | coactivator of activating protein-1 and estrogen recep- tors beta | Probable RNA-binding protein 23 (isoform 3) | CAPERbeta | FLJ10482 | Probable RNA-binding protein 23 (isoform 2) | RNA binding motif protein 23, transcript variant 3 | RNA-binding region-containing protein 4 | Probable RNA-binding protein 23 | RBM23_HUMAN

Exploring The Potential of RBM23 as A Drug Target and Biomarker

RBM23 is a gene that encodes for a protein known as Run on Module 23. It is a non-coding RNA molecule that plays a critical role in regulating gene expression in various organisms, including humans. Despite its importance, little is known about RBM23, making it an attractive drug target or biomarker. In this article, we will explore the potential of RBM23 as a drug target and its potential as a biomarker for various diseases.

Potential Drug Target

RBM23 has been identified as a potential drug target due to its involvement in various cellular processes that are crucial for human health. One of the key functions of RBM23 is its role in cell adhesion and migration. It has been shown to play a critical role in the regulation of cell-cell adhesion, which is essential for the development and maintenance of tissues and organs.

Additionally, RBM23 has been linked to the regulation of cell proliferation. It has been shown to play a negative role in the growth and survival of cancer cells, which makes it an attractive target for anti-cancer drugs.

Potential Biomarker

RBM23 has also been identified as a potential biomarker for various diseases. One of the key functions of RBM23 is its role in the regulation of gene expression, which makes it an attractive target for diseases associated with altered gene expression.

For example, RBM23 has been shown to play a critical role in the regulation of immune responses. It has been shown to play a key role in the development and maintenance of regulatory T cells, which are crucial for the immune system. Additionally, RBM23 has been shown to play a critical role in the regulation of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

Possible Interactions

RBM23 has also been shown to play a critical role in the regulation of cellular processes that are crucial for human health. It has been shown to play a key role in the regulation of cell cycle progression, which is essential for the development and maintenance of tissues and organs.

Additionally, RBM23 has been shown to play a critical role in the regulation of cell adhesion and migration. It has been shown to play a key role in the regulation of cell-cell adhesion, which is essential for the development and maintenance of tissues and organs.

Conclusion

In conclusion, RBM23 is a gene that encodes for a protein that plays a critical role in regulating gene expression in various organisms. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate further. Further studies are needed to understand the full potential of RBM23 as a drug and biomarker.

Protein Name: RNA Binding Motif Protein 23

Functions: RNA-binding protein that acts both as a transcription coactivator and pre-mRNA splicing factor (PubMed:15694343). Regulates steroid hormone receptor-mediated transcription, independently of the pre-mRNA splicing factor activity (PubMed:15694343)

The "RBM23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RBM23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RBM24 | RBM25 | RBM26 | RBM26-AS1 | RBM27 | RBM28 | RBM3 | RBM33 | RBM34 | RBM38 | RBM39 | RBM4 | RBM41 | RBM42 | RBM43 | RBM43P1 | RBM44 | RBM45 | RBM46 | RBM47 | RBM48 | RBM48P1 | RBM4B | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBM8A | RBMS1 | RBMS1P1 | RBMS2 | RBMS2P1 | RBMS3 | RBMS3-AS3 | RBMX | RBMX2 | RBMX2P1 | RBMXL1 | RBMXL2 | RBMXL3 | RBMY1A1 | RBMY1B | RBMY1D | RBMY1F | RBMY1J | RBMY2EP | RBMY2FP | RBP1 | RBP2 | RBP3 | RBP4 | RBP5 | RBP7 | RBPJ | RBPJL | RBPJP2 | RBPMS | RBPMS-AS1 | RBPMS2 | RBSN | RBX1 | RC3H1 | RC3H2 | RCAN1 | RCAN2 | RCAN3 | RCAN3AS | RCBTB1 | RCBTB2 | RCC1 | RCC1L | RCC2 | RCCD1 | RCE1 | RCHY1 | RCL1 | RCN1 | RCN1P2 | RCN2 | RCN3 | RCOR1 | RCOR2 | RCOR3 | RCSD1 | RCVRN | RD3 | RD3L | RDH10 | RDH11 | RDH12 | RDH13 | RDH14 | RDH16 | RDH5 | RDH8 | RDM1 | RDUR | RDX | RDXP2 | Reactive oxygen species (ROS)